The adenovirus E1A oncoprotein stimulates cell growth and inhibits differentiation by deregulating the normal transcription program via interaction with positive and negative cellular effectors. E1A associates with transcriptional regulatory complexes containing p400 and TRRAP involved in chromatin remodeling and decondensation. TRRAP is a component of three distinct human histone acetyltransferase (HAT) complexes: the TIP60 complex and complexes containing GCN5 or PCAF. We demonstrate here that E1A binds a TRRAP complex that contains the GCN5 acetyltransferase during a normal adenovirus infection. E1A binds GCN5 and TRRAP in vivo early after virus infection. E1A is associated with significant HAT activity in vitro that is partly attributable to GCN5. E1A represses c-Myc-and E2F-1-directed transcriptional activation in vivo by sequestering GCN5 and/or TRRAP. Our results demonstrate that E1A distinctly binds TRRAP/GCN5, p300/CBP and PCAF HAT complexes. Through interactions with multiple HAT complexes, E1A may deregulate cellular transcription programs and facilitate infection by recruiting functional HAT coactivators to viral and cellular promoter regions.
Introduction
In order to establish a productive infection, adenovirus uses the E1A protein to stimulate cell growth and inhibit differentiation by deregulating the normal transcription program of the host cell (reviewed in Frisch and Mymryk, 2002) . Two regions in the N-terminus of the E1A protein are required to reprogram cellular transcription, drive cells into S phase and transform rodent cells in cooperation with other oncogenes (Figure 1a ). These domains are conserved among adenoviruses and are referred to as conserved regions 1 and 2 (CR1 and CR2). CR1 binds the transcriptional coactivators p300 and CBP, and CR2 binds members of the retinoblastoma protein (pRb) family of tumor suppressors. The two major spliced E1A products, 13S and 12S, differ by a 46 amino-acid internal transactivation domain referred to as CR3 found in 13S. The E1A 13S and 12S proteins share the CR1 and CR2 domains that are required to bind p300/CBP and pRb.
E1A binding to p300/CBP coactivators is associated with repressed transcription of many genes, especially those involved in terminal differentiation (Frisch and Mymryk, 2002) . p300/CBP are signal-dependent transcriptional coactivators that interact with a diverse array of activators, general transcription factors and transcriptional coactivators, including SRC/ACTR and PCAF (reviewed in Chan and La Thangue, 2001 ). p300/CBP also contains intrinsic histone acetyltransferase (HAT) activity (Bannister and Kouzarides, 1996; Ogryzko et al., 1996) and functional studies in vivo have shown that this activity of CBP is required for coactivator function . p300/CBP provides an important connection between transcriptional activation, coactivator function and chromatin decondensation.
Recently, E1A has been shown to associate with transcriptional regulatory complexes involved in chromatin remodeling and decondensation. Livingston and colleagues (Fuchs et al., 2001) found that E1A binds p400. p400 is related to the yeast SWI2/SNF2 chromatin remodeling complex and modulates both transcriptional activation and repression. ATP-dependent nucleosome remodeling complexes control the access of transcription factors to promoter regions by modifying chromatin structure and nucleosome positioning. A second E1A binding partner is TRRAP (Deleu et al., 2001; Fuchs et al., 2001; Nikiforov et al., 2002) , the human homologue of the yeast protein Tra1p. Yeast Tra1p is part of large HAT/transcriptional activator complex termed SAGA (Spt-Ada-Gcn5-acetyltransferase) (reviewed in Sterner and Berger, 2000) . The yeast (y) SAGA complex contains a catalytic subunit, GCN5, transcriptional adaptor proteins, and numerous other regulatory proteins. TRRAP is a component of three distinct human HAT complexes: the TIP60 HAT complex and two complexes similar to ySAGA containing GCN5 or PCAF (Sterner and Berger, 2000) . TRRAP was first identified by its interaction with the transactivation domain of c-Myc (McMahon et al., 1998) . TRRAP recruits the human SAGA/GCN5 complex to mediate c-Myc transcriptional activation and cellular transformation (Park et al., 2001) . Similarly, E1A binding to p400 and TRRAP is required for E1A-mediated transformation (Deleu et al., 2001; Fuchs et al., 2001) .
In this report, we demonstrate that E1A binds a TRRAP complex that contains the GCN5 acetyltransferase during a normal adenovirus infection. E1A binds GCN5 and TRRAP in vivo early after virus infection. E1A is associated with significant histone acetyltransferase activity in vitro that is partly attributable to GCN5. E1A represses c-Myc-and E2F-1-directed transcriptional activation in vivo by sequestering GCN5 and/or TRRAP. Our results demonstrate that E1A distinctly binds TRAPP/GCN5, p300/CBP and PCAF HAT complexes. Through interactions with multiple HAT complexes, E1A may deregulate cellular transcription programs and facilitate infection by recruiting functional HAT coactivators to viral and cellular promoter regions.
The E1A N-terminal region causes growth inhibition when expressed in the yeast Saccharomyces cerevisiae (Kulesza et al., 2002; Shuen et al., 2002) . Growth inhibition requires several ySAGA components, including GCN5 and Tra1. We analysed E1A immunoprecipitates from wild-type Ad5-infected ATCC HeLa extracts for TRRAP and GCN5 (Figure 1b) . E1A bound TRRAP and GCN5 early after infection and in a similar manner as pRb and p300. We constructed recombinant adenoviruses that express either the wildtype E1A 12S protein or specific mutants in the Nterminal domain with well-characterized binding properties for pRb, p300/CBP and p400 (Figures 1 and 2) . As expected pRb, TRRAP, GCN5, PCAF and p300 immunoprecipitated with E1A proteins produced by wild-type Ad5 as well as the recombinant virus that only expresses the E1A 12S protein (Figure 2 ). Demonstrating the well-established importance of the N-terminal 14 amino acids of E1A, and E1A mutant dl598 (D amino acids 1-14; Whyte et al., 1989) was significantly reduced for binding TRRAP, GCN5, PCAF and p300. The E1A mutant E55 (amino acids 55-60 changed to alanine residues; Reid et al., 1998) bound TRRAP, GCN5 and PCAF efficiently, but bound weakly to p300. The E1A mutant dl1102 (D amino acids 26-35; Jelsma et al., 1989) disrupted TRRAP and GCN5 binding to E1A but did not interfere with PCAF or p300 interactions. CBP binding to wild-type and mutant E1A proteins was identical to that of p300 (data not shown). The E55 and dl1102 mutant immunoprecipitations show that PCAF Figure 1 (a) The E1A proteins. The E1A 13S/289 amino-acid and 12S/243 amino-acid proteins are shown with the conserved regions CR1, CR2 and CR3 indicated. Above the E1A protein schematics are shown the regions previously known to be involved in binding to cellular proteins. Functional properties associated with E1A proteins are shown below the E1A protein schematics (b) E1A binds to TRRAP and GCN5 during infection. ATCC HeLa cells were infected with wild-type adenovirus (WT300) at 200 particles/cell. Wholecell extracts were prepared at the indicated times (h) postinfection and incubated with anti-E1A monoclonal antibody M73. After extensive washing, immune complexes were resolved on 12.5 or 7.5% SGS-PAGE gels and analysed by Western blotting using anti-Rb (Santa Cruz #sc-50), anti-p300 (Santa Cruz #sc-584), anti-TRRAP (Santa Cruz #sc-5405), anti-GCN5 (Santa Cruz #sc-6303) or anti-E1A (NeoMarkers #MS-588) antibodies, as indicated on the right Figure 2 TRRAP/GCN5 bind to the N-terminus of E1A. ATCC HeLA cells were infected with wild-type adenovirus (WT300), E1A 12S-specific (12S) or mutant E1A 12S-specific recombinant adenoviruses at 1000 particles/cell. Whole-cell extracts were prepared 16 h postinfection and incubated with anti-E1A monoclonal antibody M73. After extensive washing, E1A immune complexes (E1A IPn) were resolved on 12.5 or 7.5% SDS-PAGE gels and analysed by Western blotting using anti-Rb, anti-p300, anti-TRRAP, anti-GCN5 and anti-PCAF (Upstate Biotechnology, #14-309), as indicated on the right E1A recruits TRRAP/GCN5 histone acetyltransferase complex SE Lang and P Hearing can bind E1A independent of TRRAP and p300/CBP. This is consistent with a report by Kouzarides and colleagues (Reid et al., 1998) showing a direct interaction between PCAF and E1A in vitro. Finally, the E1A mutant dl646N (D amino acids 30-85; Whyte et al., 1989) contains a complete deletion of CR1 that overlaps the p300/CBP and TRRAP/GCN5 binding regions, but still partially binds PCAF. This suggests that the PCAFbinding region in E1A is not as stringent as other interaction domains. These results indicate that E1A independently binds to TRRAP/GCN5, p300/CBP and PCAF HAT complexes. The same results were obtained using transient expression assays with coexpression of E1A and epitope-tagged GCN5 or PCAF (data not shown).
The ability of E1A to suppress the HAT activities of PCAF and p300/CBP remains controversial (Bannister and Kouzarides, 1996; Reid et al., 1998; Chakravarti et al., 1999; Hamamori et al., 1999) . The conflicting data led us to examine whether E1A recruits acetyltransferase activity in vivo because E1A-associated activity would shed light on the functional significance of these interactions. Thus, we assayed the HAT activity of E1A immunoprecipitates following transfection of cells with expression vectors for the E1A 13S or 12S proteins. Both E1A 13S and 12S proteins specifically recruited potent HAT activity (Figure 3a) . This finding establishes that E1A interacts with active HAT complexes. We next examined which region of E1A was required to recruit HAT activity (Figure 3b) . Deletion of the N-terminal 14 amino acids of E1A (dl598) completely eliminated associated HAT activity. In contrast, deletion of the TRRAP/GCN5-, p300/CBP-and TRRAP/GCN5-p300/CBP-specific segments of E1A (dl1102, E55 and dl646, respectively) reduced the associated HAT activity from 56 to 71%. It is difficult to show the contribution of each individual acetyltransferase to the total E1A-associated activity because of p300/CBP and GCN5 activity cannot be dissociated from PCAF activity in the E55 and dl646 mutant complexes. However, coexpression of E1A 12S with a catalytically inactive GCN5 construct reduced the E1A-associated acetyltransferase activity compared to wild-type GCN5 (data not shown). Together these results that E1A independently binds multiple active acetyletransferase complexes including TRRAP/GCN5, p300/CBP and PCAF.
To assess the importance of TRRAP/GCN5 association with E1A, we analysed the effect of E1A 12S overproduction on TRRAP-and GCN5-dependent transcriptional activation. We expected E1A to repress transient transactivation assays by sequestering TRRAP and/or GCN5 away from transcription complexes. While this may not reflect a property of E1A under natural levels of expression during adenovirus infection, we utilized this approach to provide functional evidence for E1A interactions with TRRAP and GCN5 in vivo.
We analysed c-Myc-and E2F-dependent transcription since these transcription factors have been shown to require TRRAP and GCN5 cofactors in transient expression assays (McMahon et al., 1998 (McMahon et al., , 2000 Lang et al., 2001; Flinn et al., 2002) . We assayed a GAL4-myc chimera that contains the transactivating and transforming N-terminal 262 amino acids of c-Myc fused to the GAL4 DNA-binding domain (McMahon et al., 1998) . TRAAP binds the c-Myc conserved homology box II (amino acids 129-145; MBII) and recruits GCN5 to the promoter to stimulate transcription (McMahon et al., 2000) . As expected, GAL4-myc transactivation was stimulated by the coexpression of TRRAP and GCN5, whereas Myc-mediated transcription was repressed by coexpression of E1A 12S (Figure 4a) . Interestingly, GCN5, but not TRRAP, overexpression rescued GAL4-myc transactivation from the dominant inhibitory effect of E1A 12S. This suggests either that Figure 3 E1A 12S associates with a HAT activity in vivo dependent on its p300/CBP and GCN5-binding domains. (a) Cos1 cells were transfected with either empty vector (pUC), wild-type E1A 13S or wild-type E1A 12S expression vectors, as indicated. Whole-cell extracts were prepared 24 h later and incubated with anti-E1A monoclonal antibody. E1A immune complexes were analysed in a liquid HAT assay using [H 3 ]acetyl-CoA and calf thymus histones as substrates. Histones were immobilized, washed extensively and the incorporated radioactivity was determined by liquid scintillation counting. (b) Cos1 cells were transfected with either empty vector, wild-type E1A 12S or mutant E1A 12S expression vectors, as indicated. Whole-cell extracts were prepared 24 h later and incubated with anti-E1A monoclonal antibody. After extensive washing, 5% of the immune complexes were resolved on a 15% SDS-PAGE gel and E1A levels were quantified by Western blotting. The remaining immune complexes were analysed for HAT activity as described above. The CPM data were normalized to the amount of E1A proteins immunoprecipitated as measured by quantitative Western blot analysis using AttoPhos Substrate (Promega). The results from (a) and (b) are the average of two independent experiments with s.d.'s E1A recruits TRRAP/GCN5 histone acetyltransferase complex SE Lang and P Hearing GCN5, and not TRRAP, is the limiting factor for c-Myc transactivation or that E1A directly targets GCN5 for sequestration.
Using the E2F-responsive murine E2F-1 promoter as a reporter (Hsiao et al., 1994) , we found that E1A overexpression significantly reduced E2F-1-dependent transactivation (Figure 4b ). This E1A-specific repression was partially rescued by coexpression of TRRAP. GCN5 expression stimulated the reporter, independent of exogenous E2F, and is therefore refractory to this assay (Lang et al., 2001) .
We have shown that E1A binds to TRRAP and the HAT GCN5 in vivo. This is the first demonstration that E1A binds an endogenous GCN5-containing HAT complex in mammalian cells, presumably as a multicomponent human STAGA complex that is similar to the yeast SAGA complex. This presence of PCAF in E1A complexes needs to be clarified because PCAF is thought to bind p300/CBP and can associate with TRRAP in a ySAGA-like complex (Chan and La Thangue, 2001; Sterner and Berger, 2000) . However, our results show that E1A associates with PCAF independently of both p300/CBP and TRRAP/GCN5. In addition, TRRAP is found in another HAT complex that contains TIP60 and a number of other proteins (Ikura et al., 2000) . We have not addressed the possibility that E1A binds the TRRAP/TIP60 HAT complex in addition to the TRRAP/GCN5 complex described in this report. E1A binding to these HAT complexes is early after infection with similar kinetics as pRb binding. This suggests that transactivation of early viral and cellular genes may involve E1A tethering transcriptional coactivators to promoters as well as E1A disrupting transcriptional repressing complexes. Our data show that E1A does not inhibit HAT activity attributed to p300/CBP, PCAF and TRRAP/GCN5, rather E1A recruits functional HAT activity. It is becoming clear that E1A redirects acetyltransferase activity to overcome the obstacles to a productive infection. For example, adenovirus type 12 E1A catalyzes the formation of a transcriptionally active CREB/ATF-p300/CBP ternary complex on the viral E2a promoter (Fax et al., 2000a, b) . Transcription from the E2a promoter depends on the N-terminus of E1A 12S and CBP acetyltransferase activity. The contribution of the E1A N-terminus to transactivation of viral early gene expression also was established in Ad5-infected human diploid fibroblasts (Wong and Ziff, 1994) . It will be interesting to determine whether p300/ CBP is the only transcriptional coactivator associated with Ad12 E1A, or if TRRAP/GCN5, p400 and PCAF proteins contribute to Ad12 E1A function.
These experiments indicate that E1A 12S repression of transactivation is because of direct interference with GCN5 and TRRAP cofactor functions, since overexpression of GCN5 or TRRAP rescues E1A-repressed transcriptional activity. Previous work has shown that E1A inhibits various transcriptional activators, including MyoD (Puri et al., 1997; Hamamori et al., 1999) and a GAL4-E2F1 (amino acids 380-437) chimeric protein (Trouche and Kouzarides, 1996) . Repression of these transcription factors by E1A was attributed to p300/ CBP binding, but must be re-evaluated in light of E1A interactions with TRRAP/GCN5, p400 and PCAF. It is not clear whether transcriptional repression by HAT sequestration is a relevant function of E1A 12S during adenovirus infection. However, E1A most likely sequesters important coactivators from cellular transcription factors late in infection when E1A levels are highest.
The results presented here may have implications for the ability of E1A to stimulate E2F-responsive promoters. The traditional model of E1A interactions stresses the relief of pRb repression of E2F transactivation and the concurrent gene expression promoting cell cycle progression. This establishes an environment within the cell conducive to viral and cellular DNA replication. The findings of this study complicate this model because E1A may also sequester coactivators utilized by E2F transcription factors. One explanation for the contradictory roles of E1A is found in the nature of E2F transcriptional regulation. Temporal expression of E2F-responsive genes is regulated through both transcriptional activation and repression. The genes regulated by E2F-dependent repression may be the immediate targets of E1A activity, and E1A primarily stimulates gene expression through the disruption of repressive pRb-E2F complexes. The loss of E2F repression efficiently stimulates gene expression as demonstrated by mutation of E2F-binding sites in cellular promoters (e.g. the E2F-1 promoter) that resulted in transcriptional activation during G 0 and G 1 phases of cell cycle (Hsiao et al., 1994; Johnson et al., 1994) . Thus, while E1A proteins may suppress E2F transcriptional activation by sequestering coactivators, E1A relief of pRb-E2F-mediated repression and the utilization of other transcription factors, for example, Sp1 (Hsiao et al., 1994) , is likely to activate expression of E2F-responsive promoters necessary for a productive infection.
The E1A proteins have evolved mechanisms to influence cellular decisions leading to cell division, differentiation or apoptosis. These E1A activities are mediated through binding the Rb family of tumor suppressors and via the E1A N-terminal domain that interacts with different cellular protein complexes. The N-terminal domain of E1A is required for immortalization of primary cells, transformation in conjunction with activated Ras, induction of cellular DNA synthesis, induction of apoptosis in DNA-damaged cells, relief of growth arrest by the Cdk2 inhibitor p21-Kip1, and downregulation of cellular gene expression (reviewed in Frisch and Mymryk, 2002) . The E1A region defined by mutant dl1102 (amino acids 26-35) is required for each of these E1A functions and for binding p300/CBP, p400, TRRAP, GCN5, PCAF and the Cdk inhibitor p21-CIP (Frisch and Mymryk, 2002) . The TRRAP binding sequences in E1A functionally substitute for the Nterminal region of C-myc in cellular transformation assays, presumably by recruiting TRRAP (Deleu et al., 2001; Nikiforov et al., 2002) . Further, expression of this region of E1A suppresses E1A transformation and blocks the interaction of E1A with TRRAP (Deleu et al., 2001) . That the binding of E1A to TRRAP is important in regulation of cellular growth is further substantiated by the observation that expression of antisense TRRAP inhibits E1A-mediated transformation (McMahon et al., 1998) . Clearly, the interaction of E1A with TRRAP, and likely GCN5 in a functional HAT complex, is important for E1A regulation of cellular growth control. How E1A binding to other cellular protein complexes (e.g. the p300/CBP and p400 complexes) impacts on the numerous divergent functions associated with the E1A Nterminal domain is difficult to assess since E1A mutants that distinguish these different protein-protein interactions have not been defined to date. A significant amount of work is necessary before we understand the diverse roles of E1A complexes in reprogramming cellular growth properties.
